Target intelligence / Profile preview

Pain signal transmission pathways

Molecular classification
Ion channel, G protein-coupled receptor, Other
01

Overview

Pain signal transmission pathways encompass the neural circuits from peripheral nociceptors to the spinal cord dorsal horn and higher brain centers, involving Aδ and C fibers that detect noxious stimuli like heat, mechanical damage, or chemicals. These pathways process signals through laminae I-II in the dorsal horn, where peptidergic (releasing substance P, CGRP) and non-peptidergic fibers synapse with projection neurons forming the spinothalamic tract, which relays to thalamic nuclei and cortex for localization, intensity, and emotional aspects of pain.[1][3][4] Key molecular players include voltage-gated sodium channels (e.g., Nav1.7), TRP channels (TRPV1), and receptors for prostaglandins, bradykinin, and glutamate, which sensitize during inflammation via second messengers like cAMP/PKA and PKC.[2] Dysregulation contributes to chronic pain in inflammation, neuropathy, and nociplastic conditions, making components like Nav1.7 promising for non-opioid analgesics, though complete blockade risks injury insensitivity.[1][3][6] Drugs target specific nodes, such as CGRP monoclonal antibodies for migraine or opioids for broad inhibition, but challenges include tolerance and side effects.[2][3]

Other names
Nociceptive pathwaysPain pathwaysNociception signalingSomatosensory pain pathways
02

Mechanism of action

Voltage-gated sodium channel blockade (Nav1.7); TRP channel desensitization (TRPV1); Neurokinin receptor antagonism (NK1); Opioid receptor agonism (mu, delta, kappa); CGRP receptor blockade; GABAergic inhibition

03

Biological functions

Signal transductionNociceptionSensory perception
04

Disease associations

Pain disordersInflammationNeuropathic painNeurodegenerative disease
05

Safety considerations

Loss of pain sensation leading to injuries (Nav1.7 inhibition)Off-target CNS effects (opioids)Hyperalgesia or tolerance (prolonged TRPV1 modulation)Gastrointestinal side effects (NK1 antagonists)Cardiovascular risks (CGRP modulation)
06

Interacting drugs

Nav1.7 inhibitors (e.g., experimental analgesics)

4 more in the full profile.

Beyond the preview

Go deeper on Pain signal transmission pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pain signal transmission pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call